Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives

Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies ag...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics and personalized medicine 2016-01, Vol.9 (Issue 1), p.7-16
Main Author: Myers, Meagan B
Format: Article
Language:English
Subjects:
Biomarkers
Biopsy
Breast cancer
Cancer
Cancer therapies
Care and treatment
Clinical trials
Development and progression
Diagnostic reagents
Dissection
Endocrine therapy
Epidermal growth factor
estrogen receptor
FDA approval
Feasibility studies
Food
Gene expression
Health aspects
HER2
in vitro diagnostics
Lymphatic system
Marketing
Mastectomy
Medical prognosis
Medicine
multigene assay
Oncology, Experimental
Patients
Precision medicine
Review
Surgery
Tumors
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is a multifaceted disease exhibiting both intertumoral and intratumoral heterogeneity as well as variable disease course. Over 2 decades of research has advanced the understanding of the molecular substructure of breast cancer, directing the development of new therapeutic strategies against these actionable targets. In vitro diagnostics, and specifically companion diagnostics, have been integral in the successful development and implementation of these targeted therapies, such as those directed against the human epidermal growth factor receptor 2. Lately, there has been a surge in the development, commercialization, and marketing of diagnostic assays to assist in breast cancer patient care. More recently, multigene signature assays, such as Oncotype DX, MammaPrint, and Prosigna, have been integrated in the clinical setting in order to tailor decisions on adjuvant endocrine and chemotherapy treatment. This review provides an overview of the current state of breast cancer management and the use of companion diagnostics to direct personalized approaches in the treatment of breast cancer.
ISSN:1178-7066
1178-7066
DOI:10.2147/PGPM.S56055